Metabolic Syndrome and Risks of Colon and Rectal Cancer: The European Prospective Investigation into Cancer and Nutrition Study

Metabolic syndrome (MetS) is purportedly related to risk of developing colorectal cancer; however, the association of MetS, as defined according to recent international criteria, and colorectal cancer has not been yet evaluated. In particular, it remains unclear to what extent the MetS components individually account for such an association. We addressed these issues in a nested case–control study that included 1,093 incident cases matched (1:1) to controls by using incidence density sampling. Conditional logistic regression was used to estimate relative risks (RR) and 95% CIs. MetS was defined according to the criteria of the National Cholesterol Education Program/Adult Treatment Panel III (NCEP/ATPIII), the International Diabetes Federation (IDF), and the 2009 harmonized definition. Among individual components, abdominal obesity (RR = 1.51; 95% CI: 1.16–1.96) was associated with colon cancer, whereas abnormal glucose metabolism was associated with both colon (RR = 2.05; 95% CI: 1.57–2.68) and rectal cancer (RR = 2.07; 95% CI: 1.45–2.96). MetS, as defined by each of the definitions, was similarly associated with colon cancer (e.g., RR = 1.91; 95% CI: 1.47–2.42 for MetS by NCEP/ATPIII), whereas MetS by NCEP/ATPIII, but not IDF or harmonized definition, was associated with rectal cancer (RR = 1.45; 95% CI: 1.02–2.06). Overall, these associations were stronger in women than in men. However, the association between MetS and colorectal cancer was accounted for by abdominal obesity and abnormal glucose metabolism such that MetS did not provide risk information beyond these components (likelihood ratio test P = 0.10 for MetS by NCEP/ATPIII). These data suggest that simple assessment of abnormal glucose metabolism and/or abdominal obesity to identify individuals at colorectal cancer risk may have higher clinical utility than applying more complex MetS definitions. Cancer Prev Res; 4(11); 1873–83. ©2011 AACR.

[1]  F. Clavel-Chapelon,et al.  Blood lipid and lipoprotein concentrations and colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition , 2011, Gut.

[2]  E. A. M. Gale,et al.  The metabolic syndrome: useful concept or clinical tool? Report of a WHO Expert Consultation , 2010, Diabetologia.

[3]  D. Dumitrascu,et al.  Metabolic syndrome and risk of subsequent colorectal cancer. , 2009, World journal of gastroenterology.

[4]  S. Grundy,et al.  Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International As , 2009, Circulation.

[5]  F. Clavel-Chapelon,et al.  Glycosylated hemoglobin and risk of colorectal cancer in men and women, the European prospective investigation into cancer and nutrition. , 2008, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[6]  R. Kahn.  Metabolic syndrome—what is the clinical usefulness? , 2008, The Lancet.

[7]  P. Stattin,et al.  Components of the metabolic syndrome and colorectal cancer risk; a prospective study , 2008, International Journal of Obesity.

[8]  E. Giovannucci.  Metabolic syndrome, hyperinsulinemia, and colon cancer: a review. , 2007, The American journal of clinical nutrition.

[9]  R. Kahn.  Metabolic Syndrome: Is It a Syndrome? Does It Matter? , 2007, Circulation.

[10]  Victor M Montori,et al.  Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. , 2007, Journal of the American College of Cardiology.

[11]  J. Buring,et al.  Metabolic Abnormalities and Risk for Colorectal Cancer in the Physicians' Health Study , 2006, Cancer Epidemiology Biomarkers & Prevention.

[12]  D. Albanes,et al.  A prospective study of anthropometric and clinical measurements associated with insulin resistance syndrome and colorectal cancer in male smokers. , 2006, American journal of epidemiology.

[13]  C. Friedenreich,et al.  Body size and risk of colon and rectal cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC). , 2006, Journal of the National Cancer Institute.

[14]  A. Folsom,et al.  The metabolic syndrome and risk of incident colorectal cancer , 2006, Cancer.

[15]  G. Reaven,et al.  The metabolic syndrome: is this diagnosis necessary? , 2006, The American journal of clinical nutrition.

[16]  S. Grundy.  Does a diagnosis of metabolic syndrome have value in clinical practice? , 2006, The American journal of clinical nutrition.

[17]  F. Ahmed.  Gene-Gene, Gene-Environment & Multiple Interactions in Colorectal Cancer , 2006, Journal of environmental science and health. Part C, Environmental carcinogenesis & ecotoxicology reviews.

[18]  H. Boshuizen,et al.  Reliability of biomarkers of iron status, blood lipids, oxidative stress, vitamin D, C-reactive protein and fructosamine in two Dutch cohorts , 2006, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[19]  R. Krauss,et al.  Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement , 2005, Current opinion in cardiology.

[20]  Paul Zimmet,et al.  The metabolic syndrome—a new worldwide definition , 2005, The Lancet.

[21]  W. Willett,et al.  Comparison of risk factors for colon and rectal cancer , 2004, International journal of cancer.

[22]  N E Day,et al.  European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection , 2002, Public Health Nutrition.

[23]  A. Dyer,et al.  Colorectal cancer mortality and factors related to the insulin resistance syndrome. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[24]  L. Hennighausen,et al.  Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. , 2002, Cancer research.

[25]  M. Trevisan,et al.  Markers of insulin resistance and colorectal cancer mortality. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[26]  R. L. Prentice,et al.  Retrospective studies and failure time models , 1978 .